English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NA /

21-109

A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL)

DISEASE GROUP:
Neuro-Oncology
current phase:
Phase II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: